256411-39-9

Basic information

• Product Name: (1-BOC-piperidin-4-yl)acetonitrile
• Synonyms: (1-BOC-piperidin-4-yl)acetonitrile;1-BOC-4-cyanomethylpiperidine;Tert-Butyl 4-(cyanomethyl)piperidine-1-carboxylate;1-Boc-3-CyanoMethylpiperidine;4-CyanoMethyl-piperidine-1-carboxylicacidtert-butylester
• CAS NO: 256411-39-9
• Molecular Formula: C₁₂H₂₀N₂O₂
• Molecular Weight: 224.3
• Product Categories: Amines;blocks;Carboxes
• Mol File: 256411-39-9.mol
• Article Data: 23

Chemical Properties

• Boiling Point: 344.274 °C at 760 mmHg
• Flash Point: 162.011 °C
• Appearance: /
• Density: 1.04 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.475
• Storage Temp.: 2-8°C
• PKA: -1.91±0.40(Predicted)
• CAS DataBase Reference: (1-BOC-piperidin-4-yl)acetonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: (1-BOC-piperidin-4-yl)acetonitrile(256411-39-9)
• EPA Substance Registry System: (1-BOC-piperidin-4-yl)acetonitrile(256411-39-9)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 256411-39-9(Hazardous Substances Data)

Usage

General Description

(1-Boc-piperidin-4-yl)acetonitrile is a chemical compound consisting of a piperidine ring with a tert-butoxycarbonyl (Boc) protecting group attached at the 1 position, and an acetonitrile group attached at the 4 position. It is commonly used as a building block in organic synthesis, particularly in the preparation of pharmaceuticals and agrochemicals. The Boc protecting group is often used to control reactivity and selectivity in chemical reactions, while the acetonitrile group is a versatile functional group that can participate in a wide range of synthetic transformations. (1-Boc-piperidin-4-yl)acetonitrile may also have biological activity, making it of interest in drug discovery and development. Overall, (1-Boc-piperidin-4-yl)acetonitrile is a valuable and versatile compound in the field of organic chemistry and can be used in various applications.

InChI:InChI=1/C12H20N2O2/c1-12(2,3)16-11(15)14-8-5-10(4-7-13)6-9-14/h10H,4-6,8-9H2,1-3H3

Upstream product

• 151-50-8 potassium cyanide 
• 123855-51-6 tert-butyl 4-(hydroxymethyl)piperidin-1-carboxylate 
• 41979-39-9 4-piperidone hydrochloride 
• 6457-49-4 4-piperidinemethanol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 773837-37-9 sodium cyanide 
• 161975-39-9 tert-butyl 4-(((methylsulfonyl)oxy)methyl)piperidine-1-carboxylate 
• 158407-04-6 tert-butyl 4-(bromomethyl)piperidine-1-carboxylate 
• 69719-84-2 4-(bromomethyl)piperidine 
• 1624363-23-0 3-azido-2-methylbut-3-en-2-ol 
• 1872262-73-1 1-(tert-butyl) 4-(1,3-dioxoisoindolin-2-yl) piperidine-1,4-dicarboxylate 
• 166815-96-9 N-tert-butoxycarbonyl-4-(4-toluenesulphonyloxymethyl)piperidine 
• 142374-19-4 tert-butyl 4-(formylmethyl)piperidine-1-carboxylate 
• 4248-19-5 tert-butyl carbazate 

Downstream Products

• 280110-63-6 (Z)-tert-butyl 4-(N’-hydroxycarbamimidoyl)piperidine-1-carboxylate 
• 202002-66-2 2-(piperidin-4-yl)acetonitrile 
• 713147-49-0 4-(N-hydroxycarbamimidoylmethyl)piperidine-1-carboxylic acid tert-butyl ester 
• 1264294-91-8 tert-butyl 4-(7-(1-ethoxy-2-methyl-1-oxo-3-phenylpropan-2-yl)pyrazolo[1,5-a]pyrimidin-3-yl)piperidine-1-carboxylate 
• 1264294-92-9 methyl 4-(7-(1-ethoxy-2-methyl-1-oxo-3-phenylpropan-2-yl)pyrazolo[1,5-a]pyrimidin-3-yl)piperidine-1-carboxylate 
• 713147-49-0 4-(N-hydroxycarbamimidoylmethyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 1332498-35-7 4-{5-[2-(3,4-dimethoxy-phenyl)-vinyl]-[1,2,4]oxadiazol-3-ylmethyl}-piperidine-1-carboxylic acid tert-butyl ester 
• 1332498-36-8 4-{5-[2-(3,4-dimethoxy-phenyl)-vinyl]-[1,2,4]oxadiazol-3-ylmethyl}-piperidine 
• 1332498-37-9 4-[2-(3-piperidin-4-ylmethyl-[1,2,4]oxadiazol-5-yl)-vinyl]-benzene-1,2-diol 
• 1332498-38-0 4-{5-[2-(3,4-dimethoxy-phenyl)-vinyl]-[1,2,4]oxadiazol-3-ylmethyl}-1-isopropylpiperidine 
• 1332498-39-1 4-{2-[3-(1-isopropyl-piperidin-4-ylmethyl)-[1,2,4]oxadiazol-5-yl]-vinyl}-benzene-1,2-diol 
• 1332498-40-4 [2-(4-{5-[2-(3,4-dimethoxy-phenyl)-vinyl]-[1,2,4]oxadiazol-3-ylmethyl}-piperidin-1-yl)-ethyl]-dimethyl-amine 
• 1332498-41-5 4-(2-{3-[1-(2-dimethylamino-ethyl)-piperidin-4-ylmethyl]-[1,2,4]oxadiazol-5-yl}-vinyl)-benzene-1,2-diol 
• 1353004-94-0 tert-butyl 4-(4-((2-fluoro-4-(methylsulfonyl)phenyl)amino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)piperidine-1-carboxylate 

Relevant articles and documents

SUBSTITUTED 1H-IMIDAZO[1, 2-B]PYRAZOLE-3-CARBOXAMIDE AS BRUTON TYROSINE KINASE INHIBITORS

This invention relates to a series of compounds 1H-imidazo [1, 2-b] pyrazole-3-carboxamide substituted represented by formula I used as kinase inhibitors, in particular BTK inhibitors (Bruton tyrosine kinase), and the methods of manufacture and use thereof for the treatment of an autoimmune disease, inflammatory disease, cancer and potentially allergies.

BROAD SPECTRUM ANTI-CANCER COMPOUNDS

Described herein, inter alia, are compounds for treating cancer and methods of use. This disclosure features chemical entities (e.g., small hairpin RNAs (shRNAs), micro RNA (miRNAs), small interfering RNA (siRNAs), small molecule inhibitors, antisense nucleic acids, peptides, viruses, CRISPR-sgRNAs, or combinations thereof) that inhibit one or more of m6A writers (e.g., methyltransferase like 3 (Mettl3 or MT-A70) or methyltransferase like-14 (Mettl14)), m6Am writers (e.g., phosphorylated CTD interacting factor I (PCIF 1), or Mettl3/14), m6A erasers (e.g., fat-mass and obesity-associated protein (FTO) or ALKB homolog 5 (ALKBH5)), m6Am erasers (e.g., FTO), m6A readers (e.g., YTH domain-containing family proteins (YTHs)), YTF domain family member 1 (YTHDF 1), YTF domain family member 2 (YTHDF 2), YTF domain family member 3 (YTHDF 3), or tyrosine-protein phosphatase non-receptor type 2 (PTPN2).

Structure-activity relationship study of tryptophan-based butyrylcholinesterase inhibitors

A series of tryptophan-based selective nanomolar butyrylcholinesterase (BChE) inhibitors was designed and synthesized. Compounds were optimized in terms of potency, selectivity, and synthetic accessibility. The crystal structure of the inhibitor 18 in complex with BChE revealed the molecular basis for its low nanomolar inhibition (IC50 = 2.8 nM). The favourable in vitro results enabled a first-in-animal in vivo efficacy and safety trial, which demonstrated a positive impact on fear-motivated and spatial long-term memory retrieval without any concomitant adverse motor effects. Altogether, this research culminated in a handful of new lead compounds with promising potential for symptomatic treatment of patients with Alzheimer's disease.